### Guideline Page and Request

**Internal request**  
In response to the FDA approval, consider the inclusion of tazemetostat as a treatment option for epithelioid sarcoma:

- Treatment for metastatic or locally advanced epithelioid sarcoma not eligible for complete resection (SARC-F)

**External request**  
Submission from Epizyme Inc. (01/23/20) to the NCCN Soft Tissue Sarcoma Panel to consider listing, tazemetostat as a treatment option for adults and pediatric patients aged 16 years or older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

### Panel Discussion/References

Based upon the review and discussion of the data in the noted reference(s) and the recent FDA approval, the panel consensus was to include tazemetostat as a treatment option for epithelioid sarcoma:

- For metastatic or locally advanced disease not eligible for complete resection. This is a category 2A recommendation.

See Submission for references.

### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>0</td>
<td>6</td>
<td>4</td>
</tr>
</tbody>
</table>